BNP Paribas Financial Markets
EGRX

BNP Paribas Financial Markets’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

BNP Paribas Financial Markets’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-17,976
Closed -$67K – 5593
2024
Q3 		$67K Sell
17,976
-6,426
-26% -$30.7K ﹤0.01% 3557
2024
Q2 		$137K Sell
24,402
-12,983
-35% -$56.5K ﹤0.01% 3220
2024
Q1 		$196K Sell
37,385
-51,300
-58% -$282K ﹤0.01% 3255
2023
Q4 		$464K Buy
88,685
+70,158
+379% +$693K ﹤0.01% 2831
2023
Q3 		$292K Sell
18,527
-24,492
-57% -$440K ﹤0.01% 2966
2023
Q2 		$836K Buy
43,019
+23,573
+121% +$559K ﹤0.01% 2312
2023
Q1 		$552K Sell
19,446
-5,604
-22% -$166K ﹤0.01% 2673
2022
Q4 		$732K Buy
25,050
+1,754
+8% +$55.8K ﹤0.01% 2351
2022
Q3 		$615K Buy
23,296
+20,136
+637% +$739K ﹤0.01% 2831
2022
Q2 		$140K Sell
3,160
-552
-15% -$25.4K ﹤0.01% 3230
2022
Q1 		$184K Sell
3,712
-2,685
-42% -$129K ﹤0.01% 3160
2021
Q4 		$326K Sell
6,397
-5,396
-46% -$280K ﹤0.01% 3215
2021
Q3 		$658K Buy
11,793
+7,442
+171% +$366K ﹤0.01% 2622
2021
Q2 		$186K Buy
4,351
+2,111
+94% +$87.1K ﹤0.01% 2884
2021
Q1 		$93.5K Buy
2,240
+388
+21% +$18K ﹤0.01% 3388
2020
Q4 		$86.2K Sell
1,852
-1,150
-38% -$53.8K ﹤0.01% 3286
2020
Q3 		$128K Buy
3,002
+1,209
+67% +$52.9K ﹤0.01% 2984
2020
Q2 		$86K Sell
1,793
-20,193
-92% -$1.01M ﹤0.01% 2822
2020
Q1 		$1.01M Buy
21,986
+19,649
+841% +$986K ﹤0.01% 1893
2019
Q4 		$140K Sell
2,337
-17,279
-88% -$1.03M ﹤0.01% 3124
2019
Q3 		$1.11M Buy
19,616
+431
+2% +$24.2K ﹤0.01% 1796
2019
Q2 		$1.07M Buy
19,185
+16,583
+637% +$865K ﹤0.01% 1711
2019
Q1 		$131K Buy
2,602
+2,199
+546% +$97.9K ﹤0.01% 2959
2018
Q4 		$16.2K Sell
403
-2,668
-87% -$137K ﹤0.01% 3167
2018
Q3 		$213K Hold
3,071
– – ﹤0.01% 2374
2018
Q2 		$232K Sell
3,071
-7,915
-72% -$498K ﹤0.01% 2373
2018
Q1 		$579K Sell
10,986
-574
-5% -$33.4K ﹤0.01% 2111
2017
Q4 		$618K Sell
11,560
-275
-2% -$15.3K ﹤0.01% 2338
2017
Q3 		$706K Buy
11,835
+9,379
+382% +$567K ﹤0.01% 1788
2017
Q2 		$194K Buy
2,456
+908
+59% +$74.3K ﹤0.01% 2467
2017
Q1 		$128K Buy
1,548
+202
+15% +$15K ﹤0.01% 2403
2016
Q4 		$107K Buy
1,346
+153
+13% +$11.1K ﹤0.01% 2495
2016
Q3 		$83.5K Buy
1,193
+836
+234% +$46.3K ﹤0.01% 2186
2016
Q2 		$13.8K Buy
+357
New +$14.9K ﹤0.01% 2744
2016
Q1 		– Sell
-2,132
Closed -$189K – 3132
2015
Q4 		$189K Buy
2,132
+430
+25% +$34K ﹤0.01% 1973
2015
Q3 		$126K Buy
1,702
+989
+139% +$82.3K ﹤0.01% 2240
2015
Q2 		$57.7K Buy
+713
New +$46.4K ﹤0.01% 2410
2014
Q4 		– Sell
-106
Closed -$1.34K – 3330
2014
Q3 		$1.34K Sell
106
-247
-70% -$3.06K ﹤0.01% 3968
2014
Q2 		$5.06K Buy
+353
New +$4.03K ﹤0.01% 2578

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $984M AUM 72.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $508M AUM 24.82% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

BNP Paribas Financial Markets's EGRX Position: Q4 2024 in Review

BNP Paribas Financial Markets sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 17,976 shares — an estimated $67K sold.

BNP Paribas Financial Markets first reported a position in EGRX in Q2 2014 and held it in 39 quarters. The position peaked at $1.11M in Q3 2019. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • BNP Paribas Financial Markets reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 17,976 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $67K.
  • BNP Paribas Financial Markets first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2014 and held it in 39 quarters.
  • BNP Paribas Financial Markets's Eagle Pharmaceuticals, Inc. position peaked at $1.11M in Q3 2019.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2024, filed 14 Feb 2025.